|
|
LISTEN NOW: OUR LATEST PODCAST EPISODES |
|
|
|
| Check out the latest episodes from Cell & Gene: The Podcast and Business of Biotech. As a member of the Life Science Connect community, you have access to content beyond our weekly newsletters, including our podcast series. |
|
|
THE PODCAST FOR LEADERS OF EMERGING BIOPHARMA |
|
|
|
|
| BoB@JPM: Peter Anastasiou, Capsida Biotherapeutics | From the JP Morgan Healthcare Conference in San Francisco, Peter Anastasiou, CEO of Capsida Biotherapeutics, discusses his journey from big pharma to biotech and the challenges he faces on the leading edge of first-generation gene therapies. |
|
|
| BoB@JPM: Ran Zheng, Landmark Bio | Ran Zhang was hire number one at Landmark Bio back in 2021. Today, she's CEO of the 70+ employee cell and gene therapy manufacturer. We caught up with her and Life Science Leader chief editor Ben Comer at the JP Morgan Healthcare Conference for a discussion on Landmark's role in addressing the ATMP patient access and cost reduction challenges. |
|
|
| BoB@JPM: Tom Chalberg, Ph.D., Genascence | Matt Pillar and Ben Comer review gene therapy's evolution with Dr. Tom Chalberg, Founder, Chairman, & CEO at Genascence. Listen in as they discuss ATMPS' transition from treating rare diseases to addressing common conditions like osteoarthritis, share insights on the delivery mechanism and regulatory challenges in the space, and get into the nuts and bolts of the Genascence partnership strategy. |
|
|
| BoB@JPM: Owen Hughes & Brad Sitko, XOMA Royalty | Recorded on-site at the 2025 JP Morgan Healthcare Conference, this episode explores a new approach to biotech financing with XOMA Royalty's Owen Hughes and Brad Sitko. The CEO and CIO, respectively, share an innovative royalty aggregation model that mitigates risk while enabling immediate capital access to biotech firms. |
|
|
VOICES FROM THE FRONT LINE OF CELL AND GENE DISCOVERY |
|
|
|
|
| Inside Gene Therapies For Cardiac Care With Tenaya Therapeutics' Faraz Ali | Erin Harris sits down with Faraz Ali, CEO of Tenaya Therapeutics, to explore the cutting-edge world of gene therapies for heart diseases. As Tenaya makes significant strides in developing innovative treatments, Ali shares insights on Tenaya's gene therapy platform, their in-house manufacturing capabilities, and the potential impact of their therapies on prevalent heart conditions. |
|
|
| CGT Manufacturing: Distributed & Digital with Deloitte Consulting's Omkar Kawalekar, Ph.D. | Omkar Kawalekar, Ph.D., Senior Manager, NextGen Therapies Manufacturing & Supply Chain Lead, Deloitte Consulting joins us to share his expert take on how distributed manufacturing models address capacity constraints and supply chain risks, the role of automation in reducing batch-to-batch variability, as well as the power of digital technologies in optimizing production processes. |
|
|
